The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes in radioactive iodine-refractory (RAIR) differentiated thyroid cancer (DTC) with BRAF mutation: A real-world study from the Spanish Taskforce for Neuroendocrine and Endocrine Tumors (GETNE) Thyroid Cancer registry.
 
Alejandro Garcia-Alvarez
Honoraria - Eisai; Lilly
Travel, Accommodations, Expenses - Advanz Pharma; Amgen; Eisai; Esteve; Novartis
 
Jorge Hernando
Speakers' Bureau - Advanced Accelerator Applications; Angelini Pharma; Bayer; Eisai; Ipsen; Novartis; Roche
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Eisai; Ipsen; Novartis; Roche
 
Javier Martinez Trufero
No Relationships to Disclose
 
Tiago Nunes
No Relationships to Disclose
 
Teresa Alonso Gordoa
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Eisai; Ipsen; Janssen-Cilag; Lilly; MSD Oncology; Pfizer
Research Funding - Ipsen; Janssen Oncology
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology
 
Victoria Alcazar
No Relationships to Disclose
 
Gloria Marquina
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca Spain; Deciphera; Eisai; Eisai; Eisai; Eisai; Eisai; GlaxoSmithKline; GlaxoSmithKline; Grunenthal; Grunenthal; Ipsen; Lilly; MSD; MSD; MSD Oncology; PharmaMar; Roche; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Eisai; GlaxoSmithKline; Karyopharm Therapeutics; PharmaMar; PharmaMar; Tesaro
Travel, Accommodations, Expenses - Angelini Pharma; Clovis Oncology; Eisai; Eisai; Lilly; Lilly; Lilly; Merck; MSD; MSD; Pfizer; Pfizer; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Tesaro; Tesaro
Other Relationship - GlaxoSmithKline; Tesaro; Tesaro
 
Jaime Rubio
No Relationships to Disclose
 
Pablo Ayala de Miguel
No Relationships to Disclose
 
Clara Martínez vila
No Relationships to Disclose
 
Eugenia Ortega Izquierdo
No Relationships to Disclose
 
Álvaro Ruiz-Granados
No Relationships to Disclose
 
Sandra Martinez Badal
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer